Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Thu, 15.08.2024
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2024and Provides Business Update
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac’s mRNA platform
Initiated strategic workforce reduction of ~30% by end of 2024, optimizing business [ … ]
Thu, 15.08.2024
CureVac
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
Part B expected to include up to 20 patients to generate extended data on safety, tolerability, an [ … ]
Thu, 11.07.2024
CureVac
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by Eu [ … ]
Wed, 03.07.2024
CureVac
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization
Prioritization of high-value opportunities in oncology a [ … ]
Wed, 03.07.2024
CureVac
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales miles [ … ]
Wed, 24.04.2024
CureVac
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making
Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas
TÜBINGEN, [ … ]
Thu, 18.04.2024
CureVac
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
TÜBINGEN, Germany/BOSTON, USA – April 18, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financ [ … ]
Tue, 16.04.2024
CureVac
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Agreement creates strong synergies between CureVac’s unique end-to-end mRNA capabilities and MD Anderson’s translational and clinical research expertise
Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematologic [ … ]
Fri, 05.01.2024
CureVac
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile
M [ … ]
Tue, 19.12.2023
CureVac
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation
with BioNTech SE
Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE
Decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering stron [ … ]